Mechanism of drug efficacy within the EGF receptor revealed by microsecond molecular dynamics simulation

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2394-2400

  Wan, Shunzhou ^a   Wright, David W ^a   Coveney, Peter V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; HUMAN; MOLECULAR DYNAMICS; MUTANT; PRIORITY JOURNAL; WILD TYPE;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING SITES; ENZYME STABILITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 84869219081     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0644-T     Document Type: Article

References (38)

1. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
2. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
3. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast-cancer. Lancet 1987;1:1398-402. (Pubitemid 17078859)
4. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3-S8. (Pubitemid 32938123)
5. Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods 2005;2:17-25. (Pubitemid 41131053)
6. Branden C, Tooze J. Introduction to protein structure. New York: Garland; 1999.
7. Kornev AP, Taylor SS. Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 2010;1804:440-4.
8. Garriz A, Qiu HF, Dey M, Seo EJ, Dever TE, Hinnebusch AG. A network of hydrophobic residues impeding helix alpha C rotation maintains latency of kinase Gcn2, which phosphorylates the alpha subunit of translation initiation factor 2. Mol Cell Biol 2009;29:1592-607.
9. Shin AJ, Telesco SE, Choi SH, Lemmon MA, Radhakrishnan R. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Biochem J 2011;436:241-51.
10. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Nat Acad Sci U S A 2008;105:2070-5. (Pubitemid 351439466)
11. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 2010;53:1413-37.
12. Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5. (Pubitemid 38374863)
13. Ma BY, Shatsky M, Wolfson HJ, Nussinov R. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Protein Sci 2002;11:184-97. (Pubitemid 34075781)
14. Wan S, Coveney PV. Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs. J R Soc Interface 2011;8:1114-27.
15. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 2009;5:789-96.
16. Elber R, Karplus M. Multiple conformational states of proteins - a molecular-dynamics analysis of myoglobin. Science 1987;235:318-21. (Pubitemid 17232557)
17. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011;469:236-40.
18. Wan S, Coveney PV. Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor. J Comput Chem 2011;32:2843-52.
19. Shaw DE, Deneroff MM, Dror RO, Kuskin JS, Larson RH, Salmon JK, et al. Anton, a special-purpose machine for molecular dynamics simulation. CACM 2008;51:91-7.
20. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225-36. (Pubitemid 26399746)
21. Shan YB, Klepeis JL, Eastwood MP, Dror RO, Shaw DE. Gaussian split Ewald: a fast Ewald mesh method for molecular simulation. J Chem Phys 2005;122:054101.
22. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, Florida; 2006.
23. Lang PT, Brozell SR, Mukherjee S, Pettersen EF, Meng EC, Thomas V, et al. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 2009;15:1219-30.
24. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002;9:940-4. (Pubitemid 35417064)
25. Sadiq SK, Wright DW, Kenway OA, Coveney PV. Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases. J Chem Inf Model 2010;50:890-905.
26. Dror RO, Pan AC, Arlow DH, Borhani DW, Maragakis P, Shan YB, et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci U S A 2011;108:13118-23.
27. Lindorff-Larsen K, Piana S, Dror RO, Shaw DE. How fast-folding proteins fold. Science 2011;334:517-20.
28. Csermely P, Palotai R, Nussinov R. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem Sci 2010;35:539-46.
29. Carlson HA. Protein flexibility and drug design: how to hit a moving target. Curr Opin Chem Biol 2002;6:447-52. (Pubitemid 34804766)
30. Dowell J, Minna JD, Kirkpatrick P. Erlotinib hydrochloride. Nat Rev Drug Discov 2005;4:13-4. (Pubitemid 40109581)
31. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
32. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3316-21.
33. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36. (Pubitemid 41094421)
34. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92. (Pubitemid 40271173)
35. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
36. Wright DW, Wan S, Shublaq N, Zesada S, Coveney PV. From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine. WIREs Syst Biol Med 2012. doi: 10.1002/wsbm.1186. [Epub ahead of print].
37. Yun CH, Boggon TJ, Li YQ, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27. (Pubitemid 46349842)
38. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)